Rhythm Pharmaceuticals, Inc. RYTM Unrealized gains (losses) on available-for-sale securities
Unrealized gains (losses) on available-for-sale securities at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s unrealized gains (losses) on available-for-sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s unrealized gains (losses) on available-for-sale securities?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported unrealized gains (losses) on available-for-sale securities of -$544K in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s unrealized gains (losses) on available-for-sale securities changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s unrealized gains (losses) on available-for-sale securities decreased by 5340.0% year-over-year, from -$10K to -$544K.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s unrealized gains (losses) on available-for-sale securities?
- Over 2 years (2023 to 2025), Rhythm Pharmaceuticals, Inc.'s unrealized gains (losses) on available-for-sale securities has grown at a 17.3% compound annual growth rate (CAGR), from $366K to $504K.
- What does unrealized gains (losses) on available-for-sale securities mean?
- This represents the change in the fair value of investment securities classified as available-for-sale that has not yet been realized through a sale. These unrealized gains or losses are recorded in equity rather than net income. It provides transparency into the market-driven fluctuations of the company's investment portfolio.